Introducing Co-Dx

THE SECRET IS IN THE MATH

CoDx-Logo-Medallion-Idea-v4-Final

Co-Dx™ (Co-D-X) by Co-Diagnostics, Inc. is a suite of mathematically-engineered DNA-based polymerase chain reaction (PCR) diagnostics products, producing tests for the detection of common genetic disorders and infectious diseases that are much more accuratesimpler both to create and to administer, and far less expensive.  The Co-Dx™ difference is in its advanced, proprietary mathematical models developed by Dr. Brent Satterfield, Ph.D.  Dr. Satterfield’s technologies remove the guesswork from DNA test design.

The Co-Dx™ vision is to make diagnostic testing so affordable and easy to use that it can be performed at any doctor’s office or point of care facility anywhere in the world … in both developed and emerging nations.   Co-Diagnostics has quickly become a technological leader, now at the forefront of molecular diagnostics, with a dramatic new approach.

Download PDF Product Sheet

line_title

Co-Diagnostics – innovating New Molecular Diagnostics

Advanced Mathematics

Co-Dx™ uses highly advanced mathematics and Co-Dx Design™ software for Windows® to predict how DNA and RNA will react under certain conditions. Its advanced algorithms take the guesswork out of test design, allowing designers to create highly sensitive/specific primers and probes that run virtually error free on many diagnostic platforms, including a new generation of highly mobile, low-cost test equipment.

Faster to develop and administer

The Co-Dx™ test development platform shortens the cycle for the creation of new tests utilizing Co-Dx Design™ software to weeks instead of months or years, rapidly screening millions of possible designs to find the optimal design for a specific disorder or disease.  In lieu of costly trial-and-error lab testing, Co-Dx™ designers let computers do the work, significantly shortening test development cycles.  Optimized Co-Dx™ tests run times faster on existing PCR detection equipment. And Co-Dx’s™ efficiencies are particularly impressive during PCR multiplexing (multiple tests run simultaneously).

Highly Accurate

Co-Dx™ reagents cause reactions that produce a stronger signal for PCR devices to read, detecting the presence of even a single virus. And Co-Dx™ products virtually eliminate primer dimers (common errors that occur during DNA amplification) that cause false positives and negatives.

Disruptively Inexpensive

Co-Dx™ represents a dramatic new approach to molecular diagnostics, producing tests that are far less expensive to develop and administer. Co-Dx™ tests can be performed on a new generation of highly mobile, low-cost PCR test equipment, one of which the company is co-developing for introduction in 2016. Working in tandem, Co-Dx’s™ state-of-the-art tests + mobile devices will make DNA-based diagnostics both affordable and more broadly available, breaking down historical cost barriers to worldwide markets for much-needed, accurate tests.

Co-Dx™ Applications

DISEASE DETECTION

Co-Dx™ technologies were originally developed to identify infectious diseases.  Current tests include: tuberculosis, malaria, hepatitis B and C, dengue, chagas and HIV.  Soon to be ready for distribution will be international-market tests for human papillomavirus (HPV) and gonorrhea/chlamydia.

PERSONALIZED MEDICINE

A powerhouse combination of affordable, accurate Co-Dx™ tests + a new generation of mobile, handheld devices will greatly facilitate personalized medicine for preventive care. The Co-Dx™ platform will enable healthcare companies and physicians to employ inexpensive molecular analysis to provide a healthcare roadmap for a patients based on their genetic content.

COMPANION DIAGNOSTICS

With the escalating costs of drug trials, pharmaceutical companies recognize the need to create companion diagnostics tests – a  diagnostic test partnered with a therapeutic to determine a patient’s compatibility with a treatment protocol.  Co-Dx™ is an ideal partnering platform for the development of companion diagnostics strategies.

GENETIC MARKERS

The power of the Co-Dx™ development platform lies in its ability to accurately and affordably identify genetic markers in DNA and RNA, detecting cancer markers, bacteria or viruses or to find common genetic disorders. Co-Dx™ is well-suited for labs developing specialized genetic tests.

PROACTIVE SCREENING

Co-Dx™ technology also has many applications in screening blood and other DNA samples for potential pathogens. With low-cost, Co-Dx-enabled equipment and reagents, water treatment plants can quickly and effectively test water supplies; and blood banks can test their blood supply and donors to make sure their inventory is uncontaminated.

FAMILY & SOCIAL GENETICS

Co-Dx™ technology can even be used in specialized genealogical and family history applications to determine hereditary characteristics or lineage.   The applications for Co-Dx™ technologies are virtually limitless.

CO-DIAGNOSTICS VIDEOS

CO-DIAGNOSTICS videos are not for general distribution without express written consent.

. ABOUT CO-DIAGNOSTICS DR. SATTERFIELD INTERVIEW

CO-DX ENABLES A NEW GENERATION OF PCR DEVICES

EMERGING NATIONS FIRST

A new generation of low-cost PCR devices will drive molecular diagnostics to the point of care, as well as to remote labs, pharmacies and more. It is not often that emerging nations get the latest technology first. With Co-Dx™ and this new generation of mobile devices, the developing world will likely reap early benefits.  With the support of humanitarian organizations and governments, Co-Dx™ solutions can affordably diagnose millions afflicted with common diseases like TB and malaria. Molecular diagnostics (MDx) technology has historically been available only in large labs and healthcare facilities in developed countries.  Co-Dx™ + mobile devices will facilitate the use of state-of-the-art diagnostics in regions of the world where it has previously been unaffordable and inaccessible.

PERSONALIZED MEDICINE

Early, pre-symptom disease detection has historically been available only to a small, affluent population. The combination of Co-Dx™ and highly mobile PCR devices will allow healthcare providers and physicians to proactively and affordably screen families predisposed to cancer and genetic disorders.